Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Noax Uno is an extended-release oral formulation of tramadol, a synthetic opioid analgesic. It is designed for once-daily administration to manage moderate to severe chronic pain that requires continuous, long-term opioid therapy. Tramadol, the active ingredient, exerts its effects through a dual mechanism: it acts as a mu-opioid receptor agonist and inhibits the neuronal reuptake of norepinephrine and serotonin. This formulation allows for stable plasma concentrations over a 24-hour period, improving patient compliance and providing consistent analgesia. It is typically available in strengths ranging from 100 mg to 400 mg and must be swallowed whole to maintain its controlled-release profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Noax Uno.